{"id":"pembrolizumab-and-chemotherapy-drugs","safety":{"commonSideEffects":[{"rate":"30–50","effect":"Fatigue"},{"rate":"25–40","effect":"Nausea"},{"rate":"20–35","effect":"Anemia"},{"rate":"3–5","effect":"Immune-related pneumonitis"},{"rate":"2–5","effect":"Immune-related hepatitis"},{"rate":"1–3","effect":"Immune-related colitis"},{"rate":"15–30","effect":"Neutropenia"},{"rate":"15–25","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pembrolizumab is a PD-1 inhibitor that removes the brake on T-cell-mediated anti-tumor immunity. Chemotherapy drugs induce immunogenic cell death and increase tumor antigen presentation. The combination leverages chemotherapy's cytotoxic effects with pembrolizumab's immune checkpoint blockade to improve overall anti-tumor response.","oneSentence":"Pembrolizumab blocks PD-1 to restore anti-tumor immunity, while chemotherapy drugs kill cancer cells directly; together they enhance immune activation against residual disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:18.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer (NSCLC)"},{"name":"Triple-negative breast cancer"},{"name":"Gastric or gastroesophageal junction cancer"},{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT04216316","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-14","conditions":"Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT04253964","phase":"PHASE2","title":"Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":"Nonsmall Cell Lung Cancer, Performance Status","enrollment":105},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":"Solid Tumors, Hematologic Malignancies","enrollment":3500},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT05687266","phase":"PHASE3","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-29","conditions":"NSCLC","enrollment":1350},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT04093167","phase":"PHASE2, PHASE3","title":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-05-26","conditions":"Lung Cancer","enrollment":230},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT07455019","phase":"PHASE2","title":"A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"Esophageal Cancer","enrollment":28},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT04262466","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunocore Ltd","startDate":"2020-02-25","conditions":"Select Advanced Solid Tumors","enrollment":410},{"nctId":"NCT03969446","phase":"PHASE1","title":"Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-05-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT04150640","phase":"PHASE2","title":"Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-07-13","conditions":"Esophageal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":52},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT04752826","phase":"PHASE1, PHASE2","title":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","status":"RECRUITING","sponsor":"BioInvent International AB","startDate":"2021-01-25","conditions":"Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma","enrollment":176},{"nctId":"NCT03480672","phase":"PHASE2","title":"Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2018-08-06","conditions":"HNSCC","enrollment":211},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT07404332","phase":"PHASE1","title":"5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2026-02-28","conditions":"Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor","enrollment":35},{"nctId":"NCT06052839","phase":"PHASE2","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2023-10-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","enrollment":15},{"nctId":"NCT04297605","phase":"PHASE1","title":"Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2020-05-15","conditions":"Non-small Cell Lung Cancer","enrollment":28},{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT06381154","phase":"PHASE2","title":"Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-12-06","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":25},{"nctId":"NCT04557007","phase":"","title":"Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients","status":"TERMINATED","sponsor":"Oslo University Hospital","startDate":"2020-09-01","conditions":"NSCLC","enrollment":80},{"nctId":"NCT04157517","phase":"PHASE1, PHASE2","title":"A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2019-12-12","conditions":"Neoplasms, Melanoma","enrollment":45},{"nctId":"NCT07335380","phase":"PHASE1","title":"Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-04","conditions":"Oral Cavity Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05816252","phase":"PHASE2","title":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klus Pharma Inc.","startDate":"2023-04-19","conditions":"Non-small Cell Lung Cancer","enrollment":356},{"nctId":"NCT07364305","phase":"PHASE2","title":"HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-01-01","conditions":"ICC, Advanced Cancer","enrollment":50},{"nctId":"NCT07222566","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-01-06","conditions":"Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung","enrollment":1410},{"nctId":"NCT04095689","phase":"PHASE2","title":"Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-05-12","conditions":"Triple Negative Breast Cancer, Anthracycline-refractory TNBC","enrollment":8},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT05070247","phase":"PHASE1, PHASE2","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Takeda","startDate":"2022-04-14","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma","enrollment":61},{"nctId":"NCT07174388","phase":"","title":"A Study in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"N-Power Medicine","startDate":"2026-01-07","conditions":"Non Small Cell Lung Cancer","enrollment":550},{"nctId":"NCT02819752","phase":"PHASE1","title":"PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-07-12","conditions":"Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma","enrollment":3},{"nctId":"NCT02296684","phase":"PHASE2","title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-03-25","conditions":"Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck","enrollment":67},{"nctId":"NCT06581497","phase":"","title":"ICIs With and Without MWA in Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"The First People's Hospital of Neijiang","startDate":"2022-01-01","conditions":"HCC, Therapy Adverse Effect","enrollment":52},{"nctId":"NCT06400472","phase":"PHASE1","title":"A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-20","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms","enrollment":495},{"nctId":"NCT06899126","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-10-24","conditions":"Non-small Cell Lung Cancer","enrollment":686},{"nctId":"NCT05614102","phase":"PHASE1","title":"A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-11-04","conditions":"Advanced Solid Tumors","enrollment":284},{"nctId":"NCT06529809","phase":"PHASE1, PHASE2","title":"Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-02-11","conditions":"Locally Advanced Cervical Carcinoma","enrollment":50},{"nctId":"NCT05420948","phase":"PHASE2","title":"A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2022-10-17","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms","enrollment":30},{"nctId":"NCT05860296","phase":"PHASE1, PHASE2","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","status":"TERMINATED","sponsor":"SignalChem Lifesciences Corporation","startDate":"2023-05-31","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic","enrollment":36},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT04381650","phase":"PHASE1, PHASE2","title":"A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-08-17","conditions":"Advanced or Metastatic Solid Tumors","enrollment":161},{"nctId":"NCT07275216","phase":"PHASE2","title":"Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Classic Hodgkin Lymphoma","enrollment":23},{"nctId":"NCT06230471","phase":"PHASE2","title":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-09","conditions":"Biliary Tract Neoplasms Immunotherapy","enrollment":60},{"nctId":"NCT05106127","phase":"PHASE2","title":"Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem","status":"NOT_YET_RECRUITING","sponsor":"Evergreen Therapeutics, Inc.","startDate":"2026-08","conditions":"Advanced Endometrial Cancer","enrollment":28},{"nctId":"NCT05077215","phase":"PHASE3","title":"Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Evergreen Therapeutics, Inc.","startDate":"2026-12","conditions":"Advanced Endometrial Cancer","enrollment":450},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT05117476","phase":"PHASE1","title":"A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cullinan Therapeutics Inc.","startDate":"2021-10-29","conditions":"Advanced Solid Tumor, NSCLC","enrollment":440},{"nctId":"NCT05389514","phase":"","title":"Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Providence Health & Services","startDate":"","conditions":"KRAS G12V Mutant Advanced Epithelial Cancers","enrollment":""},{"nctId":"NCT06078384","phase":"PHASE2","title":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-12-27","conditions":"Triple-negative Breast Cancer","enrollment":354},{"nctId":"NCT05929768","phase":"PHASE3","title":"Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-09-15","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":2400},{"nctId":"NCT04524689","phase":"PHASE2","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-10-26","conditions":"Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)","enrollment":57},{"nctId":"NCT06228326","phase":"PHASE1, PHASE2","title":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","startDate":"2024-04-17","conditions":"Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult","enrollment":250},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367},{"nctId":"NCT07111520","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-09-22","conditions":"Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT03383094","phase":"PHASE2","title":"Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loren Mell, MD","startDate":"2018-03-15","conditions":"Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck","enrollment":126},{"nctId":"NCT03426891","phase":"PHASE1","title":"Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-03-16","conditions":"Glioblastoma, Brain Tumor, GBM","enrollment":21},{"nctId":"NCT06822543","phase":"PHASE2","title":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)","status":"RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2025-09-30","conditions":"Lung Cancer, Non Small Cell Lung Cancer, Brain Metastases","enrollment":46},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT07190027","phase":"PHASE1, PHASE2","title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-11","conditions":"Advanced Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT04547504","phase":"PHASE3","title":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2020-12-22","conditions":"Non-small-cell Lung Cancer","enrollment":349},{"nctId":"NCT07178730","phase":"PHASE3","title":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West German Study Group","startDate":"2026-01-31","conditions":"Breast Cancer, Triple-negative Breast Cancer","enrollment":765},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT06624644","phase":"PHASE2, PHASE3","title":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","status":"RECRUITING","sponsor":"Linnaeus Therapeutics, Inc.","startDate":"2025-08-06","conditions":"Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma","enrollment":135},{"nctId":"NCT03409016","phase":"","title":"Biomarkers of Immune-Related Toxicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2018-04-18","conditions":"Cancer, Metastatic Cancer","enrollment":69},{"nctId":"NCT04879849","phase":"PHASE1","title":"A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-09-09","conditions":"Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":34},{"nctId":"NCT06364917","phase":"PHASE2","title":"DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-05-30","conditions":"Non Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT03899805","phase":"PHASE2","title":"A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-06-04","conditions":"Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":57},{"nctId":"NCT04581824","phase":"PHASE2","title":"Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2020-11-19","conditions":"Lung Cancer, Non-Small Cell","enrollment":243}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pembrolizumab and Chemotherapy drugs","genericName":"Pembrolizumab and Chemotherapy drugs","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pembrolizumab blocks PD-1 to restore anti-tumor immunity, while chemotherapy drugs kill cancer cells directly; together they enhance immune activation against residual disease. Used for Advanced or metastatic non-small cell lung cancer (NSCLC), Triple-negative breast cancer, Gastric or gastroesophageal junction cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}